Previous research has demonstrated the critical role of IL-18 in the tumor immune microenvironment, suggesting that PTX3 may be crucial in modulating the immune response in glioma (Cheng et al., 2024; Saetang et al., 2020). Here, PTX3 is linked to central nervous system cancer.